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Novel immunotherapies for oncologic treatment include anti-programmed cell 
death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) agents. These therapies 
activate the body’s inherent immune response against tumor cells by stimulating T cell 
proliferation. With the recent approval of agents such as nivolumab and pembrolizumab 
for the treatment of melanoma, lung cancer, and renal cell cancer, there is a growing need 
to better characterize their toxicity profiles. This study sought to provide a clinical and 
histologic description of the cutaneous toxicities seen in patients receiving anti-PD-1/PD-
L1 treatment. Cases of patients on anti-PD-1/PD-L1 therapy who developed cutaneous 
adverse effects were collected from a single tertiary care hospital from 2010 to 2015. 
Data regarding demographics of patients, concurrent medications, therapeutic regimen, 
clinical morphology of cutaneous lesions, and tumor response were collected. A total of 
20 patients were included in the study, with the majority of patients being treated with 
nivolumab alone. The majority of cases had a clinical morphology consisting of 
erythematous papules with scale in a variety of distributions and associated pruritus. 
Most cases were treated with topical corticosteroids and did not require discontinuation 
of oncologic treatment. Out of six patients with lung cancer who were treated with an 
anti-PD-1/PD-L1 agent alone, five patients (83%) responded to treatment. Nearly all 
cases for which biopsies were available (16 of 17 cases, 94%) showed features of 
lichenoid interface dermatitis. In addition, 47% of the cases (8 of 17) showed features of 
spongiotic dermatitis. These results support a cutaneous reaction associated with anti-PD-
1/PD-L1 therapies that has distinct clinical and histologic features. 
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Introduction 
Immunotherapy represents the next generation of anti-cancer therapy. With 
genetic, cellular, and biochemical advances, numerous immunomodulating agents have 
emerged as the most effective treatment options for cancer patients within the last several 
years. This represents a shift from targeting specific molecules important in 
tumorigenesis to disinhibiting the natural anti-tumor immune response. The idea of 
immunosurveillance was first developed in the 1950s by immunologists F. Macfarlane 
Burnet and Lewis Thomas, who both believed that immune cells of the body constantly 
surveyed host tissues for transformed tumorigenic cells (1, 2). This hypothesis was 
briefly challenged when animal models showed no differences of carcinogen-induced 
tumor development between normal and athymic mice (3). However, in the late 20th 
century, this theory was reignited when the immune response, and specifically the role of 
interferon-gamma, was found to be essential in preventing the development of 
carcinogen-induced tumors in a mouse model (4). Further support came from the clinical 
observation of higher incidences of specific types of cancer in immunodeficient 
individuals (5), as well as studies in the late 1990s and early 2000s that showed that the 
presence of an inflammatory lymphocytic infiltrate in a tumor correlated with increased 
patient survival in a variety of different cancers (6).  
However, the picture is more complicated, as cancers frequently arise in 
immunocompetent individuals. It is thought that the immune system may also 
paradoxically allow for the emergence of tumor cells that are able to escape immune 
recognition, which was first recognized in mice models when a large percentage of 
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tumors isolated from normal mice had changed to progressively growing tumors, whereas 
none of the tumors isolated from athymic mice showed this behavior (7). This has led to 
the more nuanced concept of cancer immunoediting, which encompasses both the 
protective and the tumor-sculpting functions of the immune system. This theory proposes 
three phases in which the tumor interacts with the host system: 1) elimination, during 
which the immune system is able to eradicate nascent tumor cells; 2) equilibrium, during 
which the immune system controls tumor expansion and metastasis; and finally 3) escape, 
during which tumor cells have now developed resistance to the host immune system (8).  
Communication between the cells of the immune system and tumor cells is 
complex and tightly controlled via a number of cell-cell receptor-ligand interactions, as 
well as released cytokine factors. The adaptive immune system is comprised of T 
lymphocytes which learn to distinguish various self-structures from non-self structures 
via the major histocompatibility complex (MHC) system, and B lymphocytes which 
recognize antigens via immunoglobulins. In the innate immune system, there are natural 
killer (NK) cells which recognize the lack of expression of self. Furthermore, antigen-
presenting cells can recognize non-self structures and further activate adaptive cellular 
and humoral responses. As an added regulatory step, T cell activation requires not only 
the interactions between the T cell receptor and peptide-MHC complexes, but also co-
stimulation with receptors such as CD28, which binds to either B7-1 (CD80) or B7-2 
(CD86) (9). In addition, there are also negative co-stimulatory molecules, such as 
cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1).  
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CTLA-4 Therapy 
CTLA-4 is normally expressed at low levels on the surface of naïve T cells and 
acts by competing with CD28 by binding to CD80 and CD86 (10), which effectively 
shuts off T cell receptor signaling. Mouse models demonstrated that injection with a 
solubilized form of CTLA-4 suppressed T cell-dependent antibody responses to 
exogenous antigens (11). Treatment with an anti-CTLA-4-blocking antibody caused 
regression of tumors in mouse models of colon carcinoma, fibrosarcoma, ovarian 
carcinoma, and prostate cancer (12-14).  
 Given the importance of CTLA-4 as an immune checkpoint mediator in 
preclinical animal models, monoclonal antibodies for clinical use in oncologic treatment 
have been developed. One such antibody that blocks CTLA-4 is ipilimumab, which has 
been studied most extensively in melanoma. Ipilimumab binds to CTLA-4 with a greater 
affinity than its endogenous ligands, CD80 and CD86, and in this way is able to 
dysregulate the immune response. Early phase I and II trials of ipilimumab as 
monotherapy in patients with melanoma showed clinical efficacy. In a phase I/II study of 
88 patients with unresectable stage 3 and 4 melanoma, ipilimumab was administered in 
single doses up to 20 mg/kg, multiple doses up to 5 mg/kg, and multiple doses up to 10 
mg/kg (15). Ipilimumab had activity with a disease control rate of 19%. A larger, 
randomized phase II trial involved 217 patients with stage 3 or 4 melanoma, who were 
administered 10, 3, or 0.3 mg/kg of ipilimumab every 3 weeks for four cycles followed 
by maintenance every 3 months (16). The overall response rate (ORR) in this trial, 
defined by the patients who showed either a complete or partial response to treatment, 
was 11.1% for 10 mg/kg, 4.2% for 3 mg/kg, and 0% for 0.3 mg/kg.  
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 The first randomized phase III trial compared ipilimumab alone versus 
ipilimumab in combination with a gp100 melanoma peptide vaccine versus the peptide 
vaccine alone, in patients with pretreated melanoma (17). Ipilimumab was given at a dose 
of 3 mg/kg every 3 weeks for four cycles. A total of 676 patients were included and the 
best overall response rates were 10.9%, 5.7%, and 1.5% in patients receiving ipilimumab 
alone, ipilimumab plus the vaccine, and the vaccine alone, respectively.  
 A second phase III trial randomized 502 previously untreated stage 3 or 4 
metastatic melanoma patients to receive dacarbazine in combination with either 
ipilimumab 10 mg/kg or placebo (18). A highly statistically significant improvement in 
median survival from 9.1 to 11.2 months was observed in patients receiving both 
ipilimumab and dacarbazine. In addition, the overall response rates were higher for 
ipilimumab and dacarbazine at 15.2%, compared to 10.3% in patients receiving 
dacarbazine alone. These two phase III trials demonstrated that ipilimumab had 
significant clinical efficacy in patients with advanced melanoma. In 2011, the FDA 
approved ipilimumab at a dose of 3 mg/kg for the treatment of patients with unresectable 
or metastatic melanoma. 
Anti-CTLA-4 Adverse Effects 
From clinical trials in which patients were treated with ipilimumab monotherapy, 
it appears that the most common adverse events of any grade reported in these patients 
include fatigue (12 to 56% of patients), diarrhea (12 to 46%), nausea (11 to 35%), rash 
(15 to 35%), and pruritus (15 to 35%) (16, 17, 19-21). A large proportion of adverse 
effects associated with ipilimumab therapy appear to be immune-related, and these 
immune-related adverse effects (irAEs) occur with an incidence of between 60 to 78% 
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for any grade toxicity (17, 18, 22). The incidence of grade 3 or 4 irAEs ranges anywhere 
between 7 to 56% (23). The most common organ systems affected include the skin and 
the gastrointestinal system, with symptoms including rash, pruritus, colitis, and diarrhea. 
Less common toxicities involve the liver and endocrine organs, such as hypothyroidism, 
adrenal insufficiency, and hypophysitis. There appears to be a direct correlation between 
ipilimumab dose and irAE frequency and grade (16). While the majority of clinical data 
has come from studies investigating the use of ipilimumab in melanoma, a smaller study 
investigating ipilimumab in prostate cancer patients found similar incidences of irAEs. 
The most common grade 3 and 4 toxicities included enterocolitis (15.9%, 7 of 44 
patients), hypopituitarism (13.6%, 6 of 44), hepatitis (9.1%, 4 of 44), and dermatitis 
(6.8%, 3 of 44) (24).  
Out of a large pooled analysis of multiple ipilimumab clinical trials involving 
1498 patients, dermatologic adverse effects were the most common irAE of any grade 
with an incidence of 44.9% (22). The majority of these irAEs were of grade 1 or 2 in 
severity. In terms of cutaneous toxicities specifically, the most common adverse effects 
were reported as rash and pruritus. A meta-analysis of 19 trials testing ipilimumab at 
various doses representing 760 patients total found an overall incidence of rash of any 
grade to be 24% (25). The overall incidence of high-grade rash was 2.4% and there was 
no statistical difference in the risk of rash based on dose or underlying tumor. Skin 
reactions in response to ipilimumab consist primarily of discrete, pruritic, erythematous 
papules that coalesce into thin plaques on the trunk and extensor surfaces of extremities 
(26). The rash and pruritus are typically mild in severity, can be managed with topical 
steroids and/or oral antihistamines, and are usually reversible (27). Ipilimumab treatment 
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typically does not need to be modified or discontinued. On histology, these lesions show 
perivascular infiltrates in the superficial dermis that can be comprised of both 
lymphocytes and eosinophils (26, 27). These lymphoid aggregates are composed of a 
mixture of CD4+ and CD8+ T cells. The exact mechanism leading to irAEs with 
ipilimumab treatment is not well understood. However, these findings suggest that 
immune cell infiltration may be playing a role at specific sites of toxicity. Indeed, in 
patients who develop colitis with ipilimumab treatment, biopsy of the colon demonstrates 
infiltration of neutrophils, T lymphocytes, and plasma cells (28).  
 PD-1 Therapy 
In addition to CTLA-4, another immunoregulatory molecule that has emerged as a 
therapeutic target is programmed cell death-1 (PD-1). Like CTLA-4, it is involved in 
regulating the delicate balance between immune activation and tolerance. PD-1 is a 
receptor that is expressed on both activated T and B cells, as well as monocytes (29). PD-
1 has two ligands: programmed cell death ligand-1 (PD-L1) and 2 (PD-L2), which are 
normally found on antigen-presenting cells, tumor cells, or other cells in the 
inflammatory microenvironment (29). Binding of PD-1 with its ligands leads to the 
inhibition of T cell proliferation and cytokine secretion. PD-L1 is often aberrantly 
expressed on tumors, which therefore allows for tumor-induced immune suppression by 
downregulating the T cell response. Furthermore, increased expression of PD-L1 in 
tumors was found to correlate with both decreased CD8+ T-cell infiltrate within the 
tumor, as well as with worse clinical outcome in patients in a variety of cancers, 
including ovarian, pancreatic, bladder, kidney, and melanoma (30-34). By inhibiting the 
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PD-1 receptor and blocking its interactions with its ligands, this allows for activation of 
an antitumor immune response.  
Nivolumab 
An initial phase I trial of an anti-PD-1 antibody, MDX 1106, which would later be 
renamed as nivolumab, included 39 patients with advanced metastatic melanoma, 
colorectal cancer, prostate cancer, non-small cell lung cancer (NSCLC), or renal cell 
carcinoma (RCC), who received treatment at doses between 0.3, 1, 3, or 10 mg/kg (35). 
This trial demonstrated that the therapy was well-tolerated. One patient with colorectal 
carcinoma achieved complete response, and two patients with RCC and melanoma 
experienced partial responses. Among nine of these patients whose biopsies were studied, 
PD-L1 expression on tumor cells appeared to correlate with the likelihood of tumor 
regression following treatment with PD-1 blockade. Furthermore, one patient with 
melanoma who underwent pre- and post-treatment biopsies of an axillary lymph node 
metastasis showed subsequent tumor regression after treatment accompanied by a 
moderate infiltration of CD8+ T cells that were not present prior to treatment. A 
subsequent phase II study investigated 21 patients with treatment-refractory metastatic 
NSCLC, RCC, melanoma, or prostate cancer who received MDX-1106 (36). In this study, 
one patient with RCC had a partial response, and regression of individual lesions with 
mixed overall responses was seen in two melanoma patients. Biopsy of a regressing 
lymph node metastasis showed again a moderately increased CD8+ T cell infiltrate after 
treatment. 
Over the last several years, many large-scale clinical trials have now been done. A 
phase I trial of nivolumab in 296 patients that included patients with melanoma, non-
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small cell lung cancer, renal cell carcinoma, prostate cancer, and colorectal cancer, found 
objective responses in those with NSCLC, melanoma, or RCC (37). Cumulative response 
rates were 18% among patients with NSCLC (14 of 76 patients), 28% among patients 
with melanoma (26 of 94 patients), and 27% among patients with RCC (9 of 33 patients). 
The responses were especially durable, with 20 of 31 responses (65%) lasting one year or 
more. A separate phase I trial that studied nivolumab only in melanoma, with 107 
previously treated, anti-CTLA-4-naïve patients found similar results, with an objective 
response rate of 31% and median response duration of 2 years (38). The overall survival 
was 16.8 months, with a median progression-free survival of 3.7 months.  
In a phase III study (CheckMate 066), 418 patients with previously untreated 
melanoma negative for the BRAF mutation were randomized to receive either nivolumab 
or dacarbazine (39). The primary endpoint measured was overall survival. At one year, 
the overall rate of survival was 72.9% in the nivolumab group compared to 42.1% in the 
dacarbazine group. The median progression-free survival was 5.1 months in the 
nivolumab group versus 2.2 months in the dacarbazine group. Furthermore, the objective 
response rate was 40% in the nivolumab group compared to 13.9% in the dacarbazine 
group. There was a survival benefit with nivolumab regardless of whether or not PD-L1 
was expressed in tumor cells.  
A separate phase III trial (CheckMate 037) looked at patients who had advanced 
melanoma with progression after either ipilimumab or a BRAF inhibitor if positive for a 
BRAF mutation (40). 631 patients were screened, with 272 patient randomized to receive 
nivolumab and 133 patients to receive investigator’s choice of chemotherapy. Objective 
responses were reported in 38 of the first 120 patients (31.7%) in the nivolumab group 
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versus 10.6% (5 of 47 patients) in the investigator’s choice of chemotherapy group, 
showing that nivolumab led to a greater proportion of patients achieving a response. 
In addition to melanoma, clinical trials in patients with other malignancies have 
been done, including non-small cell lung cancer. A study investigating the overall 
survival and long-term safety of nivolumab in patients with previously treated NSCLC 
showed an objective response rate of 17% (22 of 129 patients) (41). Out of this study 
group, the median progression-free survival was 2.3 months and overall survival was 9.9 
months. A separate study (CheckMate 063) investigating 117 patients specifically with 
squamous NSCLC found similar results, with a response rate of 14.5%, a median 
progression-free survival of 1.9 months, and overall survival of 8.2 months (42). 
A larger trial (CheckMate 017) also investigated the use of nivolumab in patients 
with advanced squamous cell NSCLC with disease progression on previous treatment 
compared to standard chemotherapy (43). A total of 272 patients were randomized to 
receive either nivolumab or docetaxel. The median overall survival was 9.2 months with 
nivolumab versus 6.0 months with docetaxel. The response rate was 20% with nivolumab 
compared to 9% with docetaxel, and the median progression-free survival was 3.5 
months with nivolumab versus 2.8 months with docetaxel. The study further found that 
the expression of PD-L1 in the tumor was neither prognostic nor predictive of benefit. 
As for nonsquamous NSCLC, a phase III study (CheckMate 057) randomized 
patients who had progressed after previous platinum-based chemotherapy to receive 
either nivolumab or docetaxel (44). Median overall survival was longer with nivolumab 
than with docetaxel, with 12.2 months among 292 patients in the nivolumab group versus 
9.4 months among 290 patients in the docetaxel group. The response rate was 19% with 
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nivolumab versus 12% with docetaxel. Although progression-free survival did not favor 
nivolumab over docetaxel (median, 2.3 months and 4.2 months, respectively), the rate of 
progression-free survival at one year was higher with nivolumab than with docetaxel 
(19% and 8%, respectively).  
In addition to melanoma and lung cancer, nivolumab has also been shown to have 
activity in renal cell carcinoma. An early phase I study in 34 patients with previously 
treated RCC found 10 patients (29%) who achieved objective responses (45). These 
responses were particularly durable, with a median response duration of 12.9 months. 
Median overall survival in all patients was 22.4 months. A phase II study of patients with 
metastatic RCC randomized patients to receive varying dosages of nivolumab of either 
0.3, 2, or 10 mg/kg (46). The median overall survival was 18.2 months in the 0.3 mg/kg 
group, 25.5 months in the 2 mg/kg group, and 24.7 months in the 10 mg/kg group. 
Progression-free survival and response rate showed similar trends. Median progression-
free survival was 2.7, 4.0, and 4.2 months respectively. Response rates were 20%, 22%, 
and 20%, respectively. While no clear dose-response relationship was detected, these 
results showed that nivolumab demonstrated antitumor activity across all three dosages 
studied. 
Most recently, a large phase III trial (CheckMate 025) was done involving 821 
patients with advanced RCC who had received previous treatment (47). Patients were 
randomized to receive either nivolumab or everolimus as treatment. The median overall 
survival was 25.0 months with nivolumab compared to 19.6 months with everolimus. The 
objective response rate was greater with nivolumab than with everolimus (25% versus 
5%, respectively). The median progression-free survival was 4.6 months with nivolumab 
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and 4.4 months with everolimus. This clinical trial was actually stopped early given the 
clinical benefit in overall survival shown with nivolumab.  
Given the results of these numerous clinical trials that demonstrate the improved 
clinical benefit of nivolumab compared to previous therapies, nivolumab was approved in 
2014 for patients with previously treated unresectable or metastatic melanoma. It was 
also approved in 2015 for the treatment of patients with metastatic squamous non-small 
cell lung cancer with progression on or after platinum-based chemotherapy. In late 2015, 
nivolumab was approved to treat patients with advanced renal cell carcinoma. Table 1 
summarizes the results of the clinical trials that have been done investigating nivolumab 
in various malignancies. 
Pembrolizumab 
A second antibody that inhibits PD-1 has been developed, called pembrolizumab, 
also previously known as MK-3475, and appears to have comparable efficacy and 
tolerability. Early clinical trials demonstrated its activity in melanoma patients. A study 
of 135 patients with advanced melanoma showed a response rate of 38% with no 
significant difference between patients who had received prior treatment with ipilimumab 
and those who had not (48). The overall median progression-free survival among these 
patients was longer than 7 months. A separate phase I trial of 411 patients, of which 190 
were naïve to ipilimumab and 221 had been previously treated with ipilimumab, did find 
a difference between these two patient groups (49). In the ipilimumab-treated group, the 
overall response rate was found to be 28% and in ipilimumab-naïve patients, the response 
rate was 40%. The median progression-free survival was similar in both groups, at 6 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































separate study of 173 patients who had all previously been treated with ipilimumab 
showed an overall response rate of 26% and median progression-free survival of 4.5 
months with pembrolizumab treatment (50). 
A subsequent phase II trial (KEYNOTE-002) was an international, randomized, 
controlled trial comparing two pembrolizumab doses with investigator-choice 
chemotherapy in patients with ipilimumab-refractory melanoma (51). The primary 
endpoint was progression-free survival, which was found to be improved in patients 
assigned to pembrolizumab 2 mg/kg (hazard ratio 0.57, 95% confidence interval (CI) 
0.45 to 0.73) and those assigned to pembrolizumab 10 mg/kg (HR 0.5, 95% CI 0.39 to 
0.64), compared with those assigned to chemotherapy. Median progression-free survival 
was 4.9 months averaged amongst the two dosage groups of pembrolizumab, compared 
to 2.6 months in the chemotherapy control group. The overall response rate with 
pembrolizumab was 23% compared to only 4% in the investigator-choice chemotherapy 
group.  
Another large study compared the efficacy of pembrolizumab versus ipilimumab 
in advanced melanoma patients (20). This study found a response rate of 33% in the 
pembrolizumab group compared to 12% in the ipilimumab group. Furthermore, the 
patients treated with pembrolizumab had longer progression-free survival and overall 
survival, demonstrating that pembrolizumab has more clinical benefit compared to 
ipilimumab. Estimated one-year survival rates were 71% and 58% with pembrolizumab 
and ipilimumab, respectively. 
In terms of lung cancer, only one clinical trial has been published. A large phase I 
trial assessed the efficacy of pembrolizumab in 495 patients with advanced NSCLC (52). 
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Among all patients, the objective response rate was found to be 19.4%, with a median 
duration of response of 12.5 months and median progression-free survival of 3.7 months. 
The median overall survival was 12 months. However, when looking at a subset of 73 
patients who had PD-L1 expression in 50% or more of tumor cells, the response rate was 
much improved to 45.2%, suggesting that there may be increased benefit in those patients 
whose tumors strongly express PD-L1. Numerous other clinical trials studying the 
efficacy of pembrolizumab in NSCLC are currently underway. 
Based on the results of these trials, pembrolizumab was approved in 2014 for the 
treatment of advanced melanoma after treatment with ipilimumab. In 2015, 
pembrolizumab was granted accelerated approval for the treatment of metastatic NSCLC 
in patients whose disease had progressed after other treatments and whose tumors 
specifically expressed PD-L1. Table 2 summarizes the results of recent clinical trials 
investigating pembrolizumab. 
Anti-PD-1 Adverse Effects 
The early phase I trial of nivolumab in previously treated melanoma patients 
investigated safety in terms of overall adverse effects and those that were specifically 
immune-related (38). The most common events of any grade included fatigue (32%), rash 
(23%), and diarrhea (18%). In particular regards to immune-related events, this was quite 
common as 54% of patients (58 of 107) experienced an irAE of any grade, but only 5% 
were grade 3 or 4. The most common irAEs of any grade included skin disorders (36%), 
gastrointestinal events (18%), and endocrinopathies (13%). Multiple other clinical trials 
have found similar incidences of these adverse effects. Table 1 lists the three most 

































































































































































































































































































































































































































































































































































































41%), decreased appetite (10 to 19%), gastrointestinal symptoms such as diarrhea (10 to 
19%) and nausea (10 to 15%), and cutaneous manifestations such as rash and pruritus. 
Rash appeared to be quite a common adverse effect of nivolumab, occurring in 4 to 27% 
of patients. This is with the caveat that in these oncologic clinical trials, adverse effects 
were tabulated separately as “rash” or as other more specific subsets such as “rash 
maculopapular” or “rash erythematous.” Thus, the true incidence of any sort of rash may 
be slightly higher than these numbers suggest. Pruritus was also reported in 2 to 19% of 
patients.  
Similar adverse effects and incidences have been found with pembrolizumab. In 
the phase I study of patients with ipilimumab-refractory melanoma treated with 
pembrolizumab, the most common drug-related adverse events of any grade were fatigue 
(35%), pruritus (23%), and rash (18%) (50). Adverse events that were designated by the 
investigators to be immune-related of any grade occurred in 24.5% of patients (25 of 173), 
with the most common being hypothyroidism, diarrhea, arthralgia, and rash. Table 2 
outlines the incidences of the most common adverse effects found in other clinical trials 
of pembrolizumab, showing similar incidences to the above.  Fatigue occurred in 
anywhere between 19 to 35% of patients, rash in 10 to 21%, and pruritus in 11 to 23% of 
patients. While rash was considered an immune-related adverse event, other common 
irAEs seen with pembrolizumab included pneumonitis, colitis, and hypothyroidism and 
other endocrine abnormalities (52).  
PD-L1 Therapy 
There are a few monoclonal antibodies directed against the PD-L1 ligand that 
have been developed, including atezolizumab (also known as MPDL3280A) and MDX-
17 
1105 (also known as BMS-936559). These are currently being clinically investigated in 
numerous malignancies. PD-1 inhibitors block both of the ligands PD-L1 and PD-L2, and 
could theoretically provide more robust clinical efficacy but also increased toxicity. By 
blocking PD-L1 further downstream in the pathway, this could lead to slightly decreased 
anti-tumor response but also perhaps decreased toxicity. Preliminary data show that anti-
PD-L1 agents have clinical efficacy and seem to be well-tolerated in multiple cancers. In 
an early study, 45 patients with melanoma were treated with atezolizumab as 
monotherapy (53). A response rate of 26% (9 out of 35 patients) was observed, with all 
responses ongoing or improving at time of analysis. Atezolizumab also appeared to be 
well-tolerated, with no treatment-related deaths occurring on study and the most common 
adverse effects being fatigue (59%), diarrhea (30%), and pruritus (25%). In a study of 
207 patients with various malignancies, treatment was with MDX-1105, and the patient 
group was comprised of 75 patients with NSCLC, 55 with melanoma, 18 with colorectal 
cancer, 17 with RCC, 17 with ovarian cancer, 14 with pancreatic cancer, 7 with gastric 
cancer, and 4 with breast cancer (54). An objective response was observed in 9 of 52 
patients (17%) with melanoma, 2 of 17 patients (12%) with RCC, 5 of 49 (10%) with 
NSCLC, and 1 of 17 (6%) with ovarian cancer. The most common adverse effects in this 
study were fatigue occurring in 16% of patients, infusion-related reactions in 10% of 
patients, and diarrhea in 9%. Rash and pruritus occurred in 7% and 6% of patients, 
respectively. While this study showed objective response rates that are lower than the 
large-scale trials of the anti-PD-1 agents nivolumab and pembrolizumab, whether or not 
there is a true difference remains to be seen with further investigation and larger sample 
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sizes. Further clinical trials regarding outcomes and adverse effects with anti-PD-L1 
antibodies are currently underway.  
Aims 
 While these anti-PD-1 and anti-PD-L1 therapeutic agents have shown activity in 
numerous different malignancies, they have only emerged recently within the last several 
years and remain relatively new. Thus, their safety and associated toxicity profiles are 
still being fully characterized. Data from existing clinical trials show that a large 
proportion of the associated adverse effects appear to be immune-related. These irAEs 
further include a significant proportion that are cutaneous in nature. However, in the 
large-scale oncologic trials evaluating anti-PD-1/PD-L1 agents, these cutaneous adverse 
effects are described only as “rash.” Therefore, further investigation into the specific 
characteristics of the cutaneous eruptions seen with these agents is warranted to 
determine whether they are similar to or different from other drug eruptions. Doing so 
will allow for early recognition by both oncologists and dermatologists alike and allow 
for appropriate management and minimization of the impact of these skin toxicities. This 
study sought to characterize both the clinical and histopathologic features of cutaneous 
toxicities that developed in a series of patients receiving anti-PD-1 or PD-L1 therapy. 
Methods 
 With the approval of the Yale University Institutional Review Board, cases were 
collected from Yale-New Haven Hospital from between 2010 to 2015. Patients were 
included if they were on treatment with either an anti-PD-1 or anti-PD-L1 agent alone, or 
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if there were receiving an anti-PD-1 or anti-PD-L1 agent in combination with other 
therapy, and if they were referred for dermatologic evaluation of rash. Data that was 
collected included patient demographics, concurrent medications, therapeutic regimen, 
type of disease, previous oncologic therapies, clinical morphology and distribution of 
cutaneous lesions, treatment of rash, peripheral blood eosinophil count, and tumor 
response. Consent was obtained from patients at time of their clinical evaluation to 
document photographs of their cutaneous lesions, with minimization of any identifying 
features. Concurrent medications at the time of presentation for each patient were 
recorded. The peripheral blood eosinophil count was recorded at the time of biopsy, and 
for those patients without biopsy, eosinophil count was recorded at the time of 
presentation of cutaneous toxicity. Tumor response was determined from documentation 
from the patients’ treating oncologists, and was characterized as one of four responses 
based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria: 1) complete 
response, in which there is disappearance of all target lesions, 2) partial response in 
which there is at least a 30% decrease in the sum of the size of target lesions, 3) stable 
disease, in which there is neither sufficient shrinkage to qualify for partial response nor 
sufficient increase to qualify for progressive disease, and 4) progressive disease, in which 
there is at least a 20% increase in the sum of the size of target lesions or the appearance 
of new lesions. Time to disease progression was calculated from the first dose of anti-PD-
1/PD-L1 treatment to progression, which was determined by imaging. Any other 
immune-related adverse effects that were documented were recorded. The 
histopathological features of available biopsy specimens were reviewed by two 
dermatopathologists and tabulated. For each available case, light microscopic 
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examination of tissue sections prepared with hematoxylin-eosin staining was performed. 
In addition, for three of the cases (#2, 5, and 9), a panel of immunoperoxidase stains, 
including stains for CD3, CD4, CD8, and CD20, was performed.  
Results 
 A total of 20 patients were included in this study (13 men and 7 women). The 
median age of patients at the onset of cutaneous toxicities was 62 years old (range 46 to 
86 years). Ten patients were treated with nivolumab alone, while four were treated with 
nivolumab in combination with ipilimumab. One patient was treated with nivolumab in 
combination with bevacizumab, and one patient was started on nivolumab in addition to 
erlotinib and subsequently continued on nivolumab alone. Two patients were treated with 
pembrolizumab alone, one patient was treated with the anti-PD-L1 agent atezolizumab 
alone, and one patient received atezolizumab in combination with carboplatin and 
paclitaxel. 60% of patients (12 of 20) had received prior systemic therapy for their cancer, 
with 3 of 20 patients having received prior immune checkpoint inhibitors. One of these 
patients had already received a previous course of nivolumab and ipilimumab 
combination therapy, while two patients had received therapy with ipilimumab. Table 3 
summarizes the characteristics of the included patients.  
The time of onset to cutaneous eruption was variable, with a mean time of 4 
months and a range of 3 days to 13 months. The majority of cases (80%, 16 of 20) had a 
clinical morphology consisting of erythematous papules with scale, in either a focal 
distribution such as localized lesions on an extremity or the neck (55%, 11 of 20) (Figure 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Erythematous papules with scale due to anti-PD-1/PD-L1 therapy. A) Example 
of localized lesions on the left forearm of a patient. B) Example of a generalized 





extremities (45%, 9 of 20) (Figure 1B). There were a few cases with distinct features. 
One patient (#12) developed larger 1 to 2 cm keratotic scaly plaques on the lower legs 
resembling hypertrophic lichen planus (Figure 2A). One patient (#7) had numerous pink 
thin papules and plaques forming a shawl-like distribution over the upper chest (Figure 
2B). One patient (#1) presented with scaly discrete papules on the back, chest, and 
abdomen that looked typical of Grover’s disease, or transient acantholytic dermatosis. Of 
note, two patients (#6 and 19) had lesions limited to a striking palmoplantar distribution 
with additional oral mucosal lesions.  In one of these patients (#6), there was a sudden 
onset of small 2 to 3 mm pseudovesiculated papules in coalescent plaques covering the 
palms and soles. On the soles, the plaques extended laterally onto the sides of the feet but 
did not cross Wallace’s lines (Figure 2C). In the other patient (#19), pink-red scaly thin 
papules limited to the palms and soles were larger (up to 1 cm), discrete, and not 
coalescent (Figure 2D). One patient (#14) had distinct inflammation of and around 
existing seborrheic keratoses (Figure 2E). One patient (#11) experienced within 5 days of 
starting anti-PD-1 therapy, worsening of an existing rash that had started while on 
previous treatment with ipilimumab. Four patients (#6, 9, 10, and 19) developed oral 
lesions that varied in appearance. One patient (#6) developed concurrent 1 to 2 mm 
whitish flat-topped papules with apparent Wickham’s striae on the bilateral buccal 
mucosa extending onto the lateral commissures (Figure 2F), in addition to her 
palmoplantar lesions. The other three patients (#9, 10, and 19) developed erosions 
involving the tongue, buccal mucosa, lips, and/or gingivae. Lastly, one patient (#10) 






Figure 2. Additional examples of cutaneous eruptions seen with anti-PD-1/PD-L1 
therapy. A) Hypertrophic scaly papules and plaques on the lower extremity. B) Thin pink 
papules and plaques in a shawl-like distribution over the upper chest. C) Coalescent 
plaques localized to the sole of the foot. D) Scaly, discrete papules on the palm. E) 
Inflammation of and around existing seborrheic keratoses on the back of a patient. F) 
Small white papules on the buccal mucosa. G) Erosive lesions on the penis, resembling 
erosive lichen planus. 
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Out of 20 patients, most (75%, 15 of 20) were noted to experience pruritus with 
the lesions. The most common treatment was with topical corticosteroids. One patient 
(#18) who developed two acute eruptions that appeared temporally related to erlotinib 
administration required oral prednisone. The two patients who developed palmoplantar 
lesions (#6 and 19) were treated with phototherapy, one with psoralen and ultraviolet A, 
and the other with narrow band ultraviolet B, both with improvement. Five of 20 patients 
(25%) required dose delay of the oncologic agent because of cutaneous toxicity. 
Eosinophil counts were not significantly elevated in the majority of patients (80%, 16 of 
20) at the time of cutaneous eruptions. Table 4 lists the concurrent medications at the 
time of presentation and the absolute eosinophil counts in patients at time of biopsy or at 
time of presentation if biopsy was not performed.  
Tumor response, time to progression, and development of any other immune-
related adverse effects were also assessed (Table 3). Out of six patients with melanoma, 
three had a partial response, one had stable disease, and two had progression of disease. 
Out of 11 patients with NSCLC, two patients achieved complete response, seven had a 
partial response, and two had progression of disease. Out of three patients with RCC, one 
patient had a partial response, one patient had stable disease, and one patient had 
progression of disease. Excluding three patients who had an ongoing response to 
treatment at time of data collection, the mean progression-free survival (PFS) was 23.67 
months, with a wide range between 1.73 to 75 months. This large range was due to a 
distinct phenomenon of quite prolonged PFS in those patients who experienced tumor 
response, compared to a much shorter PFS in patients who did not respond to treatment. 
When separating patients into two groups, those who experienced an objective  
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Table 4. Concurrent medications and peripheral eosinophil counts in patients. 
 
Pt. # Concurrent medications Serum eosinophils 
(absolute count 
cells/ul) 
1 Brimonidine, clopidogrel, cholecalciferol, CoQ10, iron, 
loperamide, metformin, metoprolol, simvastatin, 
tetrahydrozoline, nitroglycerin, aspirin 
1050 
2 Aspirin, metformin, coumadin, amiodarone 104 
3 Rosuvastatin, zolpidem 504 
4 Insulin 0 
5 Lorazepam, amlodipine, chlorthalidine, atenolol 212 
6 Tiotropium, montelukast, metoprolol, HCTZ, 
diphenhydramine 
252 
7 Hydrochlorothiazide, levothyroxine, tamsulosin 747 
8 Tiotropium, ipratropium-albuterol, oxycontin, oxycodone-
acetaminophen, alprazolam, fluticasone/salmeterol, 
rosuvastatin, fenofibrate, aspirin 
138 
9 Ibuprofen 84 
10 Omeprazole, prochlorperazine, sertraline, mirtazapine, 
allopurinol, atorvastatin, naproxen 
72 
11 Aspirin, atorvastatin, glipizide, lisinopril, metformin, 
metoprolol, nitroglycerin 
930 
12 Celecoxib, levetiracetam, phenobarbital, vitamin B12 135 
13 Vitamin D 310 
14 Aspirin, ibuprofen, omeprazole, zolpidem 126 
15 Atorvastatin, cholecalciferol, colchicine, rivaroxaban, 
famotidine, moxifloxacin 
304 
16 Aspirin, albuterol, famotidine, hydrocortisone, hydroxyzine, 
lorazepam, omeprazole, zolpidem, levetiracetam 
150 
17 Lorazepam, mirtazapine, morphine 66 
18 Sertraline, eszopiclone 208 
19 Omeprazole, levothyroxine, bupropion, sertraline 159 
20 Acetaminophen, atorvastatin, bupropion, tadalafil, digoxin, 
fluticasone-salmeterol, metoprolol, morphine, omeprazole, 
ondansetron, prochlorperazine, rivaroxaban, tiotropium 
0 
 
Bolded medications indicate those that have been reported to cause lichenoid drug eruptions (55, 56). 
Bolded eosinophil counts indicate those that represent a peripheral eosinophilia, defined as greater than 500 
cells/ul. 
 
response (either complete or partial), and those who experienced stable disease or 
progression of disease, the mean PFS in each group was 33.8 months versus 5.1 months, 
respectively. 
Histology was available from 17 of the 20 patients. Nearly all cases (16 cases, 
94%) showed features of lichenoid interface dermatitis (Figures 3A-C). In addition, many 
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of the cases also showed features of spongiotic dermatitis (8 cases, 47%). One case, the 
patient who developed acute eruptions in temporal association with erlotinib 
administration (#18), showed evidence of vacuolar interface changes. Of the three 
biopsies for which ancillary immunostaining was performed, all showed intradermal and 
intraepithelial lymphocytes that were CD3-positive (Figure 3D). Intradermal 
lymphocytes were CD4-positive, while intraepithelial lymphocytes were CD8-positive; 
CD20 stains were negative (Figures 3E-G). Table 3 summarizes the predominant 
histopathological patterns of each skin biopsy, and Table 5 summarizes the overall 
findings seen in the series of cases.  
 
Table 5. Summary of histologic features seen on biopsy of cutaneous eruptions 
associated with anti-PD-1/PD-L1 therapy.   
    
Number 
of cases 
% of total 
cases (n = 17) 
Reaction patterns Interface dermatitis 17 100% 
       Lichenoid 16 94% 
       Vacuolar 1 6% 
  Spongiotic dermatitis 8 47% 
Diagnostic features Altered stratum corneum  15 88% 
       Hyperkeratosis 11 65% 
       Parakeratosis 9 53% 
            Parakeratotic mounds 2 12% 
        Serum deposition 6 35% 
  Epidermal changes 13 76% 
       Premature terminal differentiation 5 29% 
       Acanthosis 4 24% 
       Irregular psoriasiform hyperplasia 3 18% 
       Atrophy 1 6% 
  Superficial reticular dermal changes 17 100% 
       Lymphocytic band-like 7 41% 
      Mixed band-like 4 24% 
       Mixed perivascular infiltrate 6 35% 
       Lymphocytic perivascular 4 24% 
       Stromal edema 9 53% 
       Pigment incontinence 6 35% 
       Red blood cell extravasation 7 41% 












































Figure 3. Photomicrographs from one representative patient showing lichenoid interface 
dermatitis (A-C; hematoxylin-eosin at 4x, 10x, and 20x respectively). Staining of 
lymphocytic infiltrate with the following immunoprofile: CD3-positive (both intradermal 
and intraepithelial lymphocytes, D), CD4-positive (intradermal lymphocytes, E), CD8-




With recent advances in cancer therapy, immunotherapies have emerged as the 
next generation of oncologic treatment. Antibodies that block either PD-1 or its ligand 
PD-L1 have shown significant clinical activity and therapeutic promise. Because these 
agents have just recently emerged within the last decade, their full toxicity profiles have 
yet to be fully characterized. The main adverse effects that have been associated so far 
with anti-PD-1 therapy include cutaneous toxicities, gastrointestinal symptoms such as 
diarrhea or nausea, fatigue, myalgia, increased aminotransferase levels, and 
hypothyroidism or other endocrinopathies (57). Cutaneous adverse effects most 
commonly include rash (4 to 27% of patients), pruritus (2 to 23%), and less frequently 
vitiligo (5 to 11%) (see Tables 1 and 2 for complete references), with comparable 
incidences seen with pembrolizumab and nivolumab. Similar adverse effects are seen 
with anti-PD-L1 antibodies and include fatigue (59%), diarrhea (30%), pruritus (25%), 
and rash (16%) (53). These adverse effects are usually manageable and do not generally 
require discontinuation of therapy.  
 While “rash” has been commonly reported as an adverse effect in many oncologic 
trials evaluating anti-PD-1/PD-L1 antibodies, further details about the specific nature of 
these cutaneous eruptions are often not completely described. Our study aimed to 
characterize both the clinical and histologic features of cutaneous toxicities associated 
with anti-PD-1/PD-L1 therapy. Our group of 20 patients represented a range of different 
therapeutic regimens, consisting of 12 patients (60%) who were treated with anti-PD-1 
monotherapy (either nivolumab or pembrolizumab alone), 4 patients (20%) who were 
treated with combination therapy of nivolumab and ipilimumab, 2 patients (10%) who 
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received PD-1 therapy (nivolumab) in addition to another agent of some kind, and 2 
patients (10%) who were treated with anti-PD-L1 monotherapy with atezolizumab. 
Despite the differences in treatment regimen, the cutaneous eruptions that were seen with 
anti-PD-1, anti-PD-L1, or combination therapy shared common characteristics. Clinically, 
the eruption seen with these agents consisted of erythematous scaly papules or plaques 
that were usually pruritic. The distribution of lesions varied, with either a small number 
of discrete papules or plaques on a limited area of the body or a generalized distribution 
of larger plaques with a predilection for the trunk. A localized or generalized distribution 
seemed to be relatively equally as likely, with an incidence of 55% and 45% in our group 
of patients, respectively. There was also a wide range in time to cutaneous presentation 
after initiation of anti-PD-1/PD-L1 therapy, ranging from 3 days to 13 months.  
While the clinical morphology varied, the histology was remarkably consistent 
amongst the patients. Nearly all of the cases for which biopsies were performed in our 
study (16 out of 17, 94%) showed lichenoid interface changes. Three biopsies for which 
immunohistochemical staining was available showed that this lichenoid infiltrate was 
composed of predominantly CD4+ T cells within the dermis, with a few CD8+ 
intraepithelial lymphocytes. It is interesting to note that previous trials showed a CD8+ T 
cell infiltrate within tumor metastases post-treatment (35, 36). In fact, one study in 
particular found a greater increase in CD8+ density from baseline to post-treatment 
biopsy that significantly correlated with a decrease in radiographic tumor size (58). Their 
findings seemed to suggest that therapeutic PD-1 blockade was effective through CD8+ T 
cells at the tumor margin. Our findings show a predominantly CD4+ T cell infiltrate, 
suggesting that there may be different mechanism at play in the target tumor cells than in 
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the skin. In addition, many of the biopsies showed concurrent features of spongiotic 
dermatitis. These two features of lichenoid interface and spongiotic changes represent a 
combination not commonly seen. A previous case series reported similar findings of 
lichenoid dermatitis on histology in three patients receiving pembrolizumab for treatment 
of melanoma (59). Clinically, the patients presented with papular lesions as well, 
primarily on the trunk and extremities, between four to nine weeks after starting 
treatment with pembrolizumab. Two of these patients had previously received 
immunotherapy with ipilimumab. All three cases showed a CD3-positive lymphocytic 
infiltrate, with a more prominent CD4+ component than CD8+, and with 10% of the T 
cells showing positive PD-1 expression. Tumor response was noted in two of the three 
patients, and consisted of one partial and one complete response. All three patients had 
relatively mild toxicities, and oncologic treatment was not discontinued. In another recent 
case series of 5 patients treated with anti-PD-1/PD-L1 agents, histologic examination 
again revealed lichenoid dermatitis with greater histiocytic infiltrates, increased 
spongiosis, and increased epidermal necrosis, compared to biopsies of non-drug-related 
lichen planus (60). No significant differences were seen in CD4:CD8 ratio or in 
expression of CD3, CD20, PD-1, CD25, Foxp3, CXCL13, or PD-L1 compared to the 
control lichenoid reactions. Our results are consistent with this, showing a cutaneous 
lichenoid eruption that is unique to anti-PD-1/PD-L1 therapy.  
While PD-1 and PD-L1 inhibitors as monotherapy have shown remarkable 
efficacy as anti-tumor agents, combination therapy with ipilimumab appears to have more 
clinical benefit for patients with melanoma. A phase I trial in 53 melanoma patients 
receiving the combination of nivolumab and ipilimumab showed a response rate of 40%, 
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compared to a response rate of 20% in patients who had previously been treated with 
ipilimumab who then received nivolumab monotherapy (61). Another phase I trial 
studied 142 previously untreated patients with melanoma (62). These patients were 
randomized to receive ipilimumab in combination with nivolumab or ipilimumab alone. 
This study found an objective response rate of 61% in the group that received 
combination therapy with ipilimumab and nivolumab versus 11% in the group that 
received ipilimumab monotherapy, with the median progression-free survival not reached 
with combination therapy and 4.4 months with ipilimumab monotherapy. A large-scale 
trial of 945 previously untreated patients with melanoma randomized them in a 1:1:1 
ratio to receive either nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone, 
with progression-free survival and overall survival as coprimary endpoints (21). While 
data on overall survival is not yet available, this study found significant differences in 
progression-free survival. The median progression-free survival was 11.5 months (95% 
confidence interval, 8.9 to 16.7) with nivolumab plus ipilimumab, as compared to 2.9 
months (95% CI, 2.8 to 3.4) with ipilimumab alone, and 6.9 months (95% CI, 4.3 to 9.5) 
with nivolumab alone. The patients were also broken down into subgroups depending on 
whether their tumors were positive or negative for expression of PD-L1 ligand. In 
patients with tumors positive for PD-L1, progression-free survival was 14 months with 
both combination therapy and with nivolumab alone, but in patients with PD-L1-negative 
tumors, PFS was longer with combination therapy than with nivolumab alone (11.2 
month versus 5.3 months). Therefore, it appears that in the specific subset of patients 
whose tumors do not strongly express PD-L1, combination therapy with ipilimumab and 
a PD-1 inhibitor is more effective. Taken together, these trials show that there is 
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significant improvement in clinical efficacy with combination therapy, and that this may 
be poised to become the next first-line treatment in melanoma.  
However, combination therapy comes with a cost and that is a higher frequency of 
irAEs. The most common adverse effects related to nivolumab and ipilimumab 
combination therapy are rash (40 to 55% of patients), pruritus (33 to 47%), diarrhea (34 
to 44%), and fatigue (35 to 38%) (21, 61). In addition to more frequent adverse effects, in 
particular those that are cutaneous, combination immunotherapy also seems to lead to 
increased severity of irAEs. One study found that the incidence of severe grade 3 or 4 
adverse effects of any kind was 53% in patients on combination therapy, compared to 
18% in patients on monotherapy with nivolumab (61). Another study found the incidence 
of grade 3 or 4 adverse events to be 54% compared to 24% in patients treated with 
ipilimumab alone (62). While our study only included four patients who were on 
combination therapy with nivolumab and ipilimumab, there were no significant 
qualitative differences amongst their cutaneous eruptions. They all developed papular 
eruptions, although interestingly, one patient also developed inflammation of and 
erythema around existing seborrheic keratoses. All the cutaneous eruptions were 
relatively mild, and none of these four patients required discontinuation of their treatment 
because of cutaneous toxicities. However, the caveat is that this sample size of four is 
quite small, and it is also possible that those adverse effects that are more likely to be 
severe may not be skin-related.  
Given the use of these agents in oncologic patients, there is much interest in 
determining whether there are predictors of which patients will respond to therapy. 
Studies have suggested that expression of the ligand PD-L1 on tumor cells may be a 
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possible marker of clinical response (63). In a clinical trial that investigated patients with 
varying malignancies, none out of 17 patients with PD-L1-negative tumors had an 
objective response to nivolumab, whereas 9 out of 25 patients (35%) with PD-L1-positive 
tumors had an objective response (37). Another study aimed to look at tumor specimens 
from 41 patients with varying cancers receiving nivolumab to explore components of the 
tumor microenvironment (64). In this study, specimens with greater than 5% expression 
on immunohistochemistry staining were considered “positive.” They found that when 
positive tumor cell PD-L1 expression was observed, it was associated with infiltrating 
immune cells including lymphocytes and histiocytes, and that the proportion of tumor 
cells expressing PD-L1 correlated with the intensity of immune cell infiltration. 
Furthermore, PD-L1 expression by tumor cells correlated significantly with objective 
response and clinical benefit. However, the presence of immune cell infiltrates and level 
of PD-L2 expression were not found to correlate with treatment response, suggesting that 
while important, it may be PD-L1 expression itself that is more closely linked to clinical 
response. Given the question of whether PD-L1 expression on tumor cells plays a 
predictive role, a large meta-analysis aimed to pool data from multiple clinical trials. 
Overall response rate was extracted from 20 phase I to III trials investigating nivolumab, 
pembrolizumab, as well as atezolizumab. A significant interaction (p<0.0001) according 
to tumor PD-L1 expression was found with an overall response rate of 34.1% in the PD-
L1 positive group and 19.9% in the PD-L1 negative group (65). While the results of these 
various studies are certainly compelling, they do not explain the whole picture. What is 
still true is that there are patients with PD-L1 negative tumors that do respond to anti-PD-
1 treatment, and the fact remains that the overwhelming majority of patients with PD-L1 
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positivity do not respond. Furthermore, the CheckMate 066 study investigated nivolumab 
in previously untreated melanoma patients and found a response rate of 52.6% (95% CI, 
40.8 to 64.3) in the PD-L1 positive group compared to 33.1% (95% CI, 25.2 to 41.7) in 
the PD-L1 negative group (39). While this may represent a trend towards some improved 
clinical benefit with PD-L1 tumor expression, the authors of this study concluded that 
given the magnitude of the clinical benefit in patients receiving nivolumab versus those 
receiving dacarbazine, the comparison arm, PD-L1 status alone would not seem to be 
useful in selecting patients for nivolumab treatment. There are further added 
inconsistencies regarding measurement of PD-L1 expression that are assay related, in that 
there is no clear consensus on which antibodies to use, which cells to stain, and what cut-
off threshold to use. Therefore, there is still no reliable clinical characteristic or 
laboratory parameter that can predict response to anti-PD-1/PD-L1 therapy.  
With ipilimumab treatment, there is evidence that immune-related adverse effects 
may be associated with response to therapy (66). A recent study sought to investigate this 
idea with PD-1 therapy. This study of 83 patients treated with pembrolizumab found that 
those patients who developed cutaneous adverse effects had significantly longer 
progression-free survival, among three different groups receiving varying dosages of 
pembrolizumab (57). One potential caveat, however, is that patients who progress 
interrupt their treatment and do not receive the same cumulative dose, thereby having less 
likelihood of developing adverse effects. A separate study investigated the association of 
vitiligo with tumor response in patients with metastatic melanoma treated with 
pembrolizumab (67). An objective complete or partial response to treatment was 
associated with a higher occurrence of vitiligo: 12 of 17 patients (71%) who developed 
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vitiligo had an objective tumor response, compared to 14 of 50 patients (28%) who did 
not develop vitiligo (p=0.002). This study also found that those patients who developed 
vitiligo had a higher frequency and severity of other irAEs. Another study of melanoma 
patients treated with nivolumab found that rash and vitiligo correlated with statistically 
significant differences in overall survival (68). This concept is intriguing, as cutaneous 
adverse effects have been shown to be associated with likelihood of response to other 
oncologic treatments, namely the rash seen with epidermal growth factor receptor 
(EGFR) inhibitors (69, 70). Overall response rates with anti-PD-1/PD-L1 agents vary 
with tumor type. As mentioned previously, the response rates in melanoma range 
between 26 and 38% with pembrolizumab (48, 50), 31 to 44% with nivolumab (21, 38), 
and approximately 25% with the anti-PD-L1 agent atezolizumab (53) (see Tables 1 and 2 
for other references). Response rates in NSCLC range between 14 to 20% for nivolumab 
(42, 43), and for pembrolizumab, the response rate was approximately 19% specifically 
in patients whose tumors expressed PD-L1 (52). In RCC, response rates range between 
20 to 29% with nivolumab (45, 46). Nivolumab and ipilimumab combination therapy is 
known to result in greater response rates of up to 40 to 61% in melanoma patients (21, 61, 
62). In our group, six patients with NSCLC were treated with monotherapy with either an 
anti-PD-1 or PD-L1 agent alone; five of these patients (83%) showed a response. In 
addition, out of four patients with melanoma treated with anti-PD-1 monotherapy, two 
responded, and out of three patients with RCC, one responded. Of the two patients who 
received nivolumab and ipilimumab combination therapy for advanced melanoma, one 
responded and one had progression of disease. Given the small sample size of patients, 
definitive conclusions about the association of cutaneous toxicities with tumor response 
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in this group cannot be made. Six out of 20 patients (30%) developed other definitive 
irAEs that were associated with anti-PD-1/PD-L1 therapy. Four of these six patients 
showed a response to therapy, which may suggest a possible association between irAE 
development and clinical response. Since the mechanism of PD-1 therapy essentially 
stimulates an immune response, it is of great interest whether development of irAEs is 
associated with clinical benefit, and this will need to be explored with further 
investigation in large-scale trials. 
Given that some patients in our study were on combination therapy, the question 
arises of whether these cutaneous eruptions were truly due to anti-PD-1 therapy or 
whether another drug might be responsible. Indeed, four of our patients were on 
combination therapy with ipilimumab and nivolumab, and one might argue that the 
clinical appearance of cutaneous eruptions from ipilimumab versus anti-PD-1 agents is 
similar, consisting of erythematous papules coalescing into thin plaques. However, 
ipilimumab eruptions have been associated with a concurrent increase in peripheral blood 
eosinophil levels (26), and eosinophilia was not seen in the majority of patients in our 
series or in the four patients who specifically received ipilimumab. Furthermore, the 
changes on histology are distinct. In contrast to the superficial, perivascular CD4-
predominant infiltrate with eosinophils that is seen with ipilimumab therapy, biopsies 
from our patients showed a lichenoid eruption. Lichenoid eruptions have not previously 
been reported with ipilimumab, epidermal growth factor receptor (EGFR) inhibitors such 
as erlotinib, bevacizumab, or traditional cytotoxic chemotherapies such as carboplatin or 
paclitaxel. Thus, it seems likely that the lichenoid eruptions are associated with anti-PD-1 
therapy. In addition, the clinical appearance and lichenoid changes on histology are 
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consistently seen amongst both anti-PD-1 agents and anti-PD-L1 agents, supporting the 
idea that this cutaneous reaction may be a direct, on-target effect of the PD-1/PD-L1 
pathway rather than a nonspecific hypersensitivity reaction.  
These findings may have implications for the pathogenesis of lichen planus (LP), 
which is a T cell-mediated disease that affects the skin and mucous membranes, and 
classically presents with flat-topped, red or purple-colored papules on the flexor surfaces 
of extremities. LP can also affect the oral mucosa, and blockade of the PD-1/PD-L1 
pathway significantly increases the proliferation of peripheral T cells in oral LP, 
suggesting an inhibitory role of PD-1 (71). Just as LP presents with localized lesions, 
perhaps the focal distribution seen in some of our patients suggests an underlying 
“unmasking” of an immune response to a pre-existing antigen that is localized to a 
specific site in the body. Only once is there blockade of the PD-1 pathway does the body 
now produce an inflammatory response to this antigen. Histologically, LP also shows a 
similar lichenoid interface dermatitis, with a dense, band-like lymphohistiocytic infiltrate 
at the dermal-epidermal junction. LP can be difficult to distinguish from a lichenoid drug 
reaction, which can show similar histologic changes, but features more suggestive of a 
drug reaction include fewer epidermal changes and a higher concentration of necrotic 
keratinocytes and eosinophils (55). Interestingly, the majority of patients in this series 
were also on concurrent medications that have been reported in the literature to cause 
lichenoid drug reactions (Table 4). Medications that have been reported to cause a 
lichenoid drug reaction include anticonvulsants, allopurinol, anti-inflammatory drugs, 
antimalarials, beta-blockers, diuretics, statins, and psychiatric drugs (55). However, these 
patients had all previously tolerated these medications, and the fact that anti-PD-1/PD-L1 
40 
therapy was the only new medication for these patients suggests it is the most likely drug 
culprit. It is possible that the administration of an anti-PD-1 or PD-L1 therapeutic agent 
may also further “unmask” an immune response to a medication that was previously 
tolerated, resulting in these lichenoid eruptions. Interestingly, one patient (#18) 
developed acute rashes that seemed to be temporally related to erlotinib administration, 
even though she had previously tolerated a course of erlotinib with no issues two years 
prior, possibly representing an activation of the immune system by anti-PD-1 therapy to 
mount a more exuberant inflammatory response.  
 In summary, the cutaneous eruptions described in this study represent a unique 
adverse effect associated with anti-PD-1 therapy that is typically papular in morphology 
with associated scale and pruritus. There appears to be a spectrum of clinical 
presentations and distributions, ranging from one or two localized lesions on an extremity 
to a more generalized, diffuse eruption. Yet, a lichenoid pattern on histology appears to 
predominate. The eruptions are usually relatively mild and typically can be adequately 
managed with topical corticosteroids. The cutaneous reaction associated with anti-PD-
1/PD-L1 therapy appears to have distinct clinical and histologic features compared to 
other immunotherapies. Further investigation is needed to determine whether there is an 
association between cutaneous adverse effects or other irAEs and tumor response. This 
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